Lipid Nanoparticles – The Enablers for Nucleic Acids Delivery

[Article Title]

Nucleic acid therapeutics have emerged as new class of potential drugs for targeting and treatment of various diseases. In recent years, there has been a considerable interest in finding appropriate technologies to formulate nucleic acids into appropriate and bioavailable dosage forms, especially the mRNA. As a result of the introduction of life saving COVID-19 vaccines, and the launch of small interfering RNA (siRNA) as polyneuropathy drug by Alnylam, the industry is renewing interests in the next generation of lipid nanoparticle technology for delivery of mRNA therapeutics for cancers, anti-inflammatory, and rare diseases, among others. Learn more about Nucleic acid therapeutics in this article from Ascendia® Pharmaceuticals, Inc.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.